Adverse Drug Reactions of Cardiovascular Classes of Medicines-Data for Bulgarian Population

• Published in: Biomedicines Vol. 12; no. 10; p. 2163
• Main Authors: Mitkova, Zornitsa, Dimova, Anita, Petrova, Guenka, Dimitrova, Maria
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 24.09.2024; MDPI
• Subjects: Age groups; Angina pectoris; Angiotensin; Angiotensin-converting enzyme inhibitors; angiotensin-converting enzyme(ACE)inhibitors; antihyperlipidemic medicines; Antihypertensives; Causality; Chronic illnesses; Disease; drug-related side effects and adverse reactions; Health care; Hypertension; Medical personnel; Mortality; Patients; Peptidyl-dipeptidase A; Pharmaceutical industry; Polypharmacy; Professionals; sartans; Side effects; Sleep disorders; Statins; Bulgaria; angiotensin-converting enzyme(ACE)inhibitors; sartans; antihyperlipidemic medicines; drug-related side effects and adverse reactions
• ISSN: 2227-9059; 2227-9059
• DOI: 10.3390/biomedicines12102163

Hypertensionis one of the most common chronic diseases, affecting more than 20% of the population. The side effects experienced due to antihypertensive medications, such as tiredness, muscle pain, and insomnia, are often a significant predictor of poor adherence to therapy. The goal of the current study is to present the frequency, type, seriousness, and severity of adverse drug reactions reported to the BDA via Individual Case Safety Reports (ICSRs) and following differentiation of messages found in more than one patient. We conducted a retrospective analysis of the reported adverse drug reactions (ADRs) reported in the Bulgarian Drug Agency database after treatment with antihyperlipidemic medicines, angiotensin-converting enzyme (ACE) inhibitors, and sartans for the period 2017-2021. Each ICSR form was observed, and data for suspected medicine and type of adverse reaction was analyzed. The total number of processed notifications for adverse drug reactions (ADRs) included in the database is 142. The highest number of ADRs was reported for ARB (58), followed by antihyperlipidemic medicines (55) and ACE inhibitors (29). Most of the assessed adverse events experienced by more than one patient fall into the probable and related categories based on the Global Introspection method classification. Therefore, they have been investigated and are consistent with exposure in the population. Cardiovascular medicines from the groups of ACE inhibitors, sartans, and statins have a high share of reported ADRs in the BDA system. Some of them are severe and need further investigation.